# Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus

> **NCT05424432** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 63 (estimated)

## Conditions studied

- Locally Advanced Esophageal Carcinoma

## Interventions

- **DRUG:** Neoadjuvant Chemotherapy
- **DRUG:** Neoadjuvant Toripalimab
- **RADIATION:** Short Course Neoadjuvant Radiotherapy

## Key facts

- **NCT ID:** NCT05424432
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-29
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2022-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05424432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05424432, "Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05424432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*